AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase

Quick Summary:

Oncology pipeline led by first-in-class treatment for patients suffering from colorectal cancer with minimal residual disease (CRC MRD)REDWOOD CITY, Calif., Sept.27, 2024 (GLOBE NEWSWIRE) -- AmMax Bio, Inc., a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that it will present at the Oppenheimer Healthcare Private Company Showcase in New York City on Tuesday, October 1, 2024.

The Company’s pipeline includes AMB-066, for treating patients with colorectal cancer with minimal residual disease (CRC MRD), AMB-051, a locally administered injection for treating patients with tenosynovial giant cell tumor (TGCT), and AMB-104, a novel antibody-drug conjugate for the treatment of acute myeloid leukemia (AML).

The Company’s AMB-066 program is on track to initiate enrollment in a phase 2 proof of concept study in the fourth quarter to treat patients with colorectal cancer with minimal residual disease (CRC MRD).

Read Quick SummarySave Time

or

Article Details

Author / Journalist: AmMax Bio, Inc.

Category: Technology

Markets: China

Topics: Amb-066 Cancer Minimal Pipeline Ammax Disease Colorectal Company’s Patients Company Innovative

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-09-27 @ 12:33:00 (14 hours ago)

News Timezone: GMT +8:00

News Source URL: globenewswire.com

Language: English

Article Length: 395 words

Reading Time: 3 minutes read

Sentences: 15 lines

Sentence Length: 27 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © GlobeNewswire

News ID: 22750821

View Article Analysis

About GlobeNewswire

Main Topics: Technology

Official Website: globenewswire.com

Update Frequency: 24 posts per day

Year Established: 1998

Headquarters: China

News Last Updated: 9 hours ago

Coverage Areas: China

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #116

Publisher Details

Frequently Asked Questions